Connect with us

Hi, what are you looking for?

Emerging Technologies

FDA Gives Bexson Pre-IND Guidance for Ketamine Formulation Delivered by Wearable Pump

Bexson Biomedical announced today that it received pre-investigational new drug guidance from the FDA for its ketamine compound therapy.

FDA Gives Bexson Pre-IND Guidance for Ketamine Formulation Delivered by Wearable Pump

Bexson Biomedical announced today that it received pre-investigational new drug guidance from the FDA for its ketamine compound therapy.

Santa Barbara, California-based Bexson develops the patented BB106 formulation, a ketamine therapy delivered through a wearable, subcutaneous patch pump in development with Stevanato Group.

According to a news release, having reached the milestone of pre-IND guidance, Bexson plans to expand its ketamine development program to address mental health conditions including treatment-resistant depression and suicidality.

“We are pleased with the clear guidance we received from FDA regarding our preclinical and clinical programs developing BB106,” Bexson Biomedical CEO Gregg Peterson said in the release. “FDA approval is a long process, but every milestone reached is one step closer to providing patients with an alternative to opioids for pain management.”

Future clinical trials will test the effect the drug-device combination has in acute pain management as an alternative to opioid pain medications or as an added therapy to lower the need for opioids after serious surgeries, Bexson said. With FDA guidance, the company is now applying BB106 toward mental health conditions.

“Our subcutaneous ketamine formulation and pump technology has been modular by design, allowing us to tune dosing profiles to a variety of mental health conditions as our program advances,” added Bexson Co-Founder & CSO Dr. Jeffrey Becker. “We are designing our parenteral ketamine delivery system to be convenient, controlled and consistent.  This can solve many of the problems that still exist in office-based delivery of ketamine for depression and suicidal ideation, but also for ketamine-assisted trauma therapy.”

The post FDA gives Bexson pre-IND guidance for ketamine formulation delivered by wearable pump appeared first on Drug Delivery Business.

Seen on Drug Delivery Business: Article Link

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Latest News

Diagnostics

PocDoc, the digital health platform and personal diagnostics provider, has launched what it says is a world-first smartphone-based test for cardiovascular disease.

HealthTech

Focused on connecting startups in the Medtech industry with potential investors, this can't miss event features the globe's most promising companies

BioTechnology

The technology could greatly aid spinal surgeons in planning surgical interventions in advance.   

Exclusives

Emerging HealthTech company, Stasis Labs, Inc. intends to bridge the gap between clinicians and their patients with an all-in-one FDA-cleared hardware and software solution,...

You May Also Like

Exclusives

Today & Tomorrow: Digital Solutions in HealthTech Plug “digital healthcare solutions” into Google, and the results are clear: digital tools have taken the healthcare...

Exclusives

In Delray Beach, Florida, an emerging biopharma company, Cyrano Therapeutics, is planning a clinical trial using approved theophylline via a new intranasal pathway of...

Exclusives

Software as a Medical Device (SaMD) is driving innovation in the HealthTech space and is more popular than ever — completely upending the way...

Exclusives

The sky’s the limit for HealthTech PR and looking past traditional strategies to nontraditional avenues for engagement will allow agencies to stand out.